Immune-inflammatory proteome of elite ice hockey players before and after SARS-CoV-2 infection

Debbie Maurer¹, Elena Barletta¹, Anja Heider¹, Nino Stocker¹, Alexandra Wallimann¹, Michael Villiger¹, Beat Villiger¹, Katja Baerenfaller¹, Cezmi Akdis¹, and Walter Kistler¹

¹Universität Zurich Schweizerisches Institut für Allergie- und Asthmaforschung

May 3, 2022

Immune-inflammatory proteome of elite ice hockey players before and after SARS-CoV-2 infection

Keywords: COVID-19, proteomics, inflammation, immune response, athletes

To the Editor

Coronavirus disease 19 (COVID-19) is an infectious disease transmitted mainly through aerosol spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and in most cases leads mild to moderate respiratory illness, which usually resolves within 5-7 days.¹ Regular moderate-to-vigorous exercise has been associated with a strong and timely immune response against infections, thus reducing susceptibility to acute respiratory illness, and also protecting from severe COVID-19 outcomes.²,³ Frequent high intensity training has also been proposed to enhance vaccine-induced cellular and humoral immunity.² However, long-term high-intensity physical activity and stressors associated with elite sports (e.g., environmental, psychological) might cause hyperinflammation in some individuals and increase the risk of respiratory illness, and ice hockey players are among those winter sport athletes, who have the highest incidence in that context.³,⁴ Proteomic profiling of COVID-19 patients has proven valuable in the discovery of novel biomarkers associated with disease susceptibility, course, complications and severity,⁵ but so far there are no reports of COVID-19 proteomic studies in athletes. Herein, we examined the immune-inflammatory proteome of elite ice hockey players before and after a team-wide COVID-19 outbreak with the omicron BA.1 variant in December 2021.

Serum blood samples and questionnaire data were obtained from 24 players of a Swiss National League ice hockey team 3 months prior to COVID-19 and from the same players within 1-2 weeks after nasal swab PCR-confirmed SARS-CoV-2 infection, and of 20 controls, that are non-ice hockey players after recent recovery from COVID-19. Written informed consent was obtained from all study participants, and the protocol was approved by the responsible ethics committee (Kantonale Ethikkommission Zürich, Ref. 2019-02002). Proximity extension assay (PEA) technology by OLINK was used for targeted proteomic serum analyses of 180 proteins measured in the OLINK immune response and inflammation panels (92 proteins each, 4 overlaps). Immune-inflammatory profiles of ice hockey players were compared at two time points (pre- and post-COVID-19). Additionally, post-COVID-19 profiles of ice hockey players were compared to the post-COVID-19 control group for reference.

Ice hockey players and control subjects reported comparable rates of previous SARS-CoV-2 infections, atopic comorbidities (asthma, allergic rhinitis), regularly occurring upper respiratory tract infections (URTI), fever and recurrent herpes labialis (Table 1). COVID-19 vaccination history did not differ between athletes and controls. Control subjects reported a higher prevalence of symptoms in general, and respiratory symptoms specifically.
PEA-based proteomic analyses of serum samples from elite ice hockey players identified 28 differentially expressed proteins, involved in immune response and inflammation (Figure 1, A and D), with a rather distinct representation of biological process networks. While similar networks were found to be present at both sampling time points, specifically, lymphocyte proliferation (CXCL12, CD40, PRKCQ, TNFSF14 pre-COVID-19 and TRAF2, IRAK4, CASP-8 post-COVID-19) and innate inflammatory response (PRKCQ, IRAK1 pre-COVID-19 and ofTRAF2, IRAK4 post-COVID-19) (Figure 1, E and F), the post-COVID-19 profile was uniquely marked by an increase in proteins involved in innate immune response to viral infection, neutrophil activation, IL-12/-15/-18 and IFNγ-signaling (Figure 1, F). This last finding therefore may reflect how the immune system responds efficiently to COVID-19, where a timely release of antiviral interferons seems to be essential.\(^3\)

In our principal component analysis (PCA), while we could clearly separate athletes pre- and post-infection (Figure 1, B), post-COVID-19 comparison of ice hockey players with post-COVID-19 samples of the control non-ice hockey players group revealed similar proteomic patterns, with only CCL11 showing a significantly higher expression in the control group (Figure 1, C). Of note, levels ofCCL11 have recently been found to be elevated in patients experiencing cognitive symptoms ("brain fog") after mild COVID-19 compared to those without such symptoms.\(^6\) However, we did not assess incidence of post- or long-COVID-19 symptoms in our cohorts.

To conclude, we found that immune-inflammatory proteomic profiles in serum of elite ice hockey players differ significantly pre- and post-COVID-19. The cause for this observation might be multifactorial, e.g., direct impact of the recent SARS-CoV-2 infection, seasonal changes, or training-related influences on sampling timepoints. Although proteomic profiles generally did not differ between athletes and control subjects post-COVID-19, the higher incidence of symptomatic disease in the control group warrants follow-up studies to investigate the potential impact of athletic workloads on (SARS-CoV-2) infection susceptibility, disease course and vaccination response, as well as to identify associated biomarkers.

| Ice Hockey Players (n=24) | Post-COVID-19 Controls (n=20) |
|--------------------------|-------------------------------|
| **Age (range), sex**     |                               |
| Age (range), sex          | 26.6 (18 – 38), male          | 30.5 (21 – 43), male |
| Symptoms (any), n (%)     | 12 (54 %*)                    | 19 (95 %)          |
| Respiratory symptoms, n  |                               |
| Cough                    | 8 (36 %*)                     | 16 (80 %)          |
| Breathlessness           | 7 (36 %)                      | 16 (100 %)         |
| Prior SARS-CoV-2 infection, n (%) | 7 (29 %) | 3 (15 %) |
| Number of vaccinations, n (%) | none at least 1 | 3 (12 %) |
| (incomplete)             | 21 (88 %)                     | 6 (26 %)          |
| (basic immunization)      | 6 (26 %)                      | 7 (29 %)          |
| (boostered)               | 8 (33 %)                      | 3 (12 %)          |
| Vaccine, n (%) Moderna (Spikevax®) | 18 (86%) | 13 (72%) |
| Pfizer/BioNTech (Comirnaty®) | 3 (14%) | 4 (22%) |
| Johnson & Johnson (Janssen®) | 0 (0 %) | 1 (6%) |
| Asthma, n (%)             | 2 (8%)                        | 4 (21 %)          |
| Allergic rhinitis, n (%)  | 3 (4%)                        | 5 (25 %)          |
| Regular URTI or fever, n (%) | 2 (9 %**) | 1 (5 %) |
| Recurrent herpes labialis, n (%) | 5 (22 %**) | 3 (16 %) |

\(^*\) n = 22; ** n = 23
Table 1: Basic characteristics of included ice hockey players and control subjects. Abbreviations: COVID-19, coronavirus disease 19; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; URTI, upper respiratory tract infection.

Figure legend

Figure 1: Differentially expressed inflammation- and immune response-related proteins pre- and post-COVID-19 in ice hockey players. A: Heatmap showing differentially expressed proteins among athletes pre- and post-COVID-19, as well as post-COVID controls; B: Principal Component Analysis (PCA) of ice hockey players pre- and post-COVID-19; C: Scattered boxplot and heatmap of protein CCL11 (**: adjP=0.0035); D: Volcano plot of differentially expressed proteins measured by OLINK multiplex assays. Welch 2-sample t-test was used to compare pre- and post-COVID-19 athlete samples (confidence level 0.95). Correction for multiple testing done by Benjamini-Hochberg method. Statistically significant proteins shown in red (adjP <0.05); E, F: Ratio of significantly different proteins for different immune response and inflammation process networks to all proteins measured) in pre- (E) and post-COVID-19 athletes (F). Abbreviations: adjP, adjusted P value; Ctrl, control group; IH, ice hockey players; NS, non-significant.

Author list
Debbie J. Maurer*1,2, Elena Barletta*3,4, Anja Heider3, Nino Stocker3, Alexandra Wallimann1, Michael Villiger1,5, Beat Villiger1,6, Katja Bärenfaller3,4, Cezmi A. Akdis1,3, Walter Kistler1,5

*Maurer and Barletta equal first author contribution.

Affiliations
1. Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland
2. Division of Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland
3. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
4. Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
5. Department of Sports Medicine, Hospital Davos, Davos, Switzerland
6. Medical Center Bad Ragaz, Bad Ragaz, Switzerland

Acknowledgements
This work has been supported by Vontobel-Stiftung and the Center for Data Analysis, Visualization and Simulation (DAViS) funded by the Swiss canton of Grisons.

Conflict of interests
The authors declare that they have no conflicts of interest.

Supplementary material
Additional material can be found in the online supplementary of this letter.

References
1. Hull JH, Loosemore M, Schwellnus M. Respiratory health in athletes: facing the COVID-19 challenge. Lancet Respir Med.2020;8(6):557-558.
2. Nieman DC. Exercise Is Medicine for Immune Function: Implication for COVID-19. Curr Sports Med Rep. 2021;20(8):395-401.
3. Maurer DJ, Liu C, Xepapadaki P, et al. Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers. Allergy. 2022;77(4):1216-1230.
4. Orysiak J, Witek K, Zembron-Lacny A, Morawin B, Malczewska-Lenczowska J, Sitkowski D. Mucosal immunity and upper respiratory tract infections during a 24-week competitive season in young ice hockey
players. *J Sports Sci.* 2017;35(13):1255-1263.

5. Suhre K, Sarwath H, Engelke R, et al. Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies. *Front Immunol.* 2021;12:781100.

6. Fernández-Castañeda A, Lu P, Geraghty AC, et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. *bioRxiv.* 2022.